380 related articles for article (PubMed ID: 33272366)
1. VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins.
Balling M; Afzal S; Varbo A; Langsted A; Davey Smith G; Nordestgaard BG
J Am Coll Cardiol; 2020 Dec; 76(23):2725-2735. PubMed ID: 33272366
[TBL] [Abstract][Full Text] [Related]
2. Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study.
Wadström BN; Pedersen KM; Wulff AB; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1144-1155. PubMed ID: 38511326
[TBL] [Abstract][Full Text] [Related]
3. Very Low-Density Lipoprotein Cholesterol May Mediate a Substantial Component of the Effect of Obesity on Myocardial Infarction Risk: The Copenhagen General Population Study.
Johansen MØ; Nielsen SF; Afzal S; Vedel-Krogh S; Davey Smith G; Nordestgaard BG
Clin Chem; 2021 Jan; 67(1):276-287. PubMed ID: 33409531
[TBL] [Abstract][Full Text] [Related]
4. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease.
Karpe F; Hellénius ML; Hamsten A
Metabolism; 1999 Mar; 48(3):301-7. PubMed ID: 10094104
[TBL] [Abstract][Full Text] [Related]
5. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
[TBL] [Abstract][Full Text] [Related]
7. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.
Millar JS; Lichtenstein AH; Cuchel M; Dolnikowski GG; Hachey DL; Cohn JS; Schaefer EJ
J Lipid Res; 1995 Jun; 36(6):1155-67. PubMed ID: 7665994
[TBL] [Abstract][Full Text] [Related]
8. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
Marston NA; Giugliano RP; Melloni GEM; Park JG; Morrill V; Blazing MA; Ference B; Stein E; Stroes ES; Braunwald E; Ellinor PT; Lubitz SA; Ruff CT; Sabatine MS
JAMA Cardiol; 2022 Mar; 7(3):250-256. PubMed ID: 34773460
[TBL] [Abstract][Full Text] [Related]
9. Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity.
Pont F; Duvillard L; Florentin E; Gambert P; Vergès B
Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1726-32. PubMed ID: 12377756
[TBL] [Abstract][Full Text] [Related]
10. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
11. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque.
Rapp JH; Lespine A; Hamilton RL; Colyvas N; Chaumeton AH; Tweedie-Hardman J; Kotite L; Kunitake ST; Havel RJ; Kane JP
Arterioscler Thromb; 1994 Nov; 14(11):1767-74. PubMed ID: 7947602
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
13. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
Arad Y; Ramakrishnan R; Ginsberg HN
J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
[TBL] [Abstract][Full Text] [Related]
14. Quantitative and qualitative derangement of apolipoprotein B-containing lipoproteins as a risk factor for diabetic macroangiopathy in nonobese NIDDM subjects.
Harano Y; Kageyama A; Nakao Y; Hara Y; Suzuki M; Sato A; Ikebuchi M; Shinozaki K; Tsushima M
Diabetes; 1996 Jul; 45 Suppl 3():S31-4. PubMed ID: 8674886
[TBL] [Abstract][Full Text] [Related]
15. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.
Sacks FM; Alaupovic P; Moye LA; Cole TG; Sussex B; Stampfer MJ; Pfeffer MA; Braunwald E
Circulation; 2000 Oct; 102(16):1886-92. PubMed ID: 11034934
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.
Johannesen CDL; Mortensen MB; Langsted A; Nordestgaard BG
J Am Coll Cardiol; 2021 Mar; 77(11):1439-1450. PubMed ID: 33736827
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
18. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
[TBL] [Abstract][Full Text] [Related]
19. Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial.
Doi T; Langsted A; Nordestgaard BG
Atherosclerosis; 2024 Jun; 393():117556. PubMed ID: 38678642
[TBL] [Abstract][Full Text] [Related]
20. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
